TFFP TFF Pharmaceuticals, Inc: Enterprise Value to EBITDA Ratio
TFF Pharmaceuticals (TFFP) has ceased operations and closed all projects, moving toward the sale of its intellectual property to settle liabilities. Current price action on GURU.Markets, where EV/EBITDA stands at , helps track this process. The business previously developed powder-based inhaled medications to eliminate the need for injections. Growth was constrained by strict FDA oversight, medical lobbying, and patent protection for freezing methods.
Comprehensive metric breakdowns and analytics for tffpharma.com (TFFP)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity TFF Pharmaceuticals|TFFP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio TFF Pharmaceuticals, Inc.|TFFP - Company Cumulative Indebtedness|Debts to Book Capitalization TFF Pharmaceuticals, Inc|TFFP - Long-Term Liabilities|Company Short-Term Debts TFF Pharmaceuticals|Quick Liquidity Indicator tffpharma.com
- financial results and valuation multiples details:
TFFP - Final Profit|Expected Profit TFF Pharmaceuticals|TFFP - Market Cap to Net Income|Forward P/E Multiple TFF Pharmaceuticals|TFFP - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TFF Pharmaceuticals, Inc|TFFP - Operating profit EBITDA|Earnings per share for the last twelve months TFF Pharmaceuticals|TFFP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months tffpharma.com|TFFP - Net earnings per share growth this year|Earnings growth forecast for next year TFF Pharmaceuticals
General company analysis:TFF Pharma TFFP
TFF Pharmaceuticals is optimizing costs by outsourcing the production of inhalation drugs to contract manufacturing organizations (CMOs), which eliminates the need for the company to own capital-intensive plants. This strategy directly impacts the EV/EBITDA calculation, which relates the total enterprise value to its operating profit before depreciation and interest. By analyzing the EV/EBITDA multiple trends on GURU.Markets, an investor determines the fairness of the asset's market price relative to its actual ability to generate cash flow.
Direct competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|ANI Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MNKD (MannKind Corp)|Amphastar - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio PCRX|SPRY: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio TBPH (theravance.com)|Enterprise Value to EBITDA Ratio AQST|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Business Value to Operating Income Before Depreciation EPRX|BioHarvest Sciences Inc. - EV/EBITDA Multiple|EXOZ - EV/EBITDA Multiple|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Entera Bio - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|Enterprise Value to EBITDA Ratio abvcpharma.com (ABVC)|EV/EBITDA Multiple CPIX|EV/EBITDA Multiple Quantum BioPharma Ltd. (QNTM)|EV/EBITDA Multiple FGEN (FibroGen Corp)|TELO - Enterprise Value to EBITDA Ratio|Rani Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Synergy CHC Corp|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|Lexaria Bioscience Corp. (LEXX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PULM|PTHL (Pheton) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APM|Total Company Value to Operating Income Before Depreciation Ratio lyratherapeutics.com|EV/EBITDA Multiple IBO (Impact BioMedical)|TNFA - Enterprise Value to EBITDA Ratio|cbdMD Corp - EV/EBITDA Multiple|PRFX - EV/EBITDA Multiple|altamiratherapeutics.com (CYTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LIPO (lipella.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OptiNose|Pieris Pharmaceuticals Inc (PIRS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PROC (Procaps Group SA)|Enterprise Value to Operating Income Before Depreciation Ratio PTPI|EV/EBITDA Multiple QLI (Qilian International)|SLRN (acelyrin.com) - Company Value to Operating Income Before Depreciation Ratio
